@US10 silence since XanaHES announcement, page-8

Thanks @US10, good to hear you are still with us.

I hope your limited access to ASX isn't too restrictive. Here several brokers allow direct access to US stocks, but I guess it doesn't work in the other direction.

Yes, I'll try not to be added to the customer base, even if there will be shareholder discounts.

There is some shorting, but it's only minor. See www.shortman.com.au for code ACW.

It's very likely that XanaHES has residual positive news, because the 30mg cohort is yet to start.

As for XanADu, I'm not hopeful because they've already had months to find and announce anything of residual value.

Thanks again for contributing.

II